Related Experiment Video

Updated: May 9, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Trends in long-term mechanical circulatory support for advanced heart failure in the UK

Akan Emin1, Chris A Rogers, Jayan Parameshwar

  • 1Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK.

European Journal of Heart Failure
|August 1, 2013
PubMed

Insights

Ventricular assist device (VAD) use increased significantly in the UK, with a shift towards advanced third-generation devices. This transition improved patient survival rates for those awaiting heart transplantation.

Area of Science:

  • Cardiology
  • Medical Devices
  • Surgical Outcomes

Background:

  • Heart transplantation (HTx) is constrained by donor organ availability.
  • Ventricular assist devices (VADs) are crucial for managing advanced heart failure.
  • Long-term VAD support serves as a vital bridge to HTx.

Purpose of the Study:

  • To analyze UK activity and trends in long-term VAD support.
  • To evaluate the outcomes of VAD therapy as a bridge to HTx.
  • To assess the impact of VAD device generation on patient survival.

Main Methods:

  • Retrospective analysis of 247 patients receiving VAD support between February 2004 and March 2011.
  • Categorization of patients into three distinct eras based on implantation dates.
  • Comparison of outcomes based on VAD device generation (first, second, and third).

Main Results:

  • VAD activity increased substantially over the study period, with a notable rise in third-generation device utilization (from <6% to 78%).
  • Median duration of left ventricular assist device (LVAD) support significantly extended from 141 to 578 days.
  • One-year survival rates improved with newer device generations, reaching 76.9% for third-generation devices, though overall survival trends showed variability (P=0.21).

Conclusions:

  • VAD utilization and support duration have markedly increased.
  • A significant shift towards third-generation VADs has occurred.
  • Improved survival is associated with the adoption of advanced VAD technology.
Abstract

Keywords:
ECMOHeart transplantationMechanical circulatory support (MCS)Survivalventricular assist device (VAD)

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...